Granahan Investment Management LLC Lowers Position in Azenta, Inc. $AZTA

Posted by on Jul 26th, 2026

Granahan Investment Management LLC trimmed its stake in shares of Azenta, Inc. (NASDAQ:AZTA – Free Report) by 80.0% in the 1st quarter, HoldingsChannel.com reports. The fund owned 40,996 shares of the company’s stock after selling 163,680 shares during the period. Granahan Investment Management LLC’s holdings in Azenta were worth $866,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Caitong International Asset Management Co. Ltd increased its holdings in shares of Azenta by 2,067.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock worth $27,000 after purchasing an additional 765 shares during the last quarter. Assetmark Inc. increased its stake in Azenta by 54.1% in the 4th quarter. Assetmark Inc. now owns 832 shares of the company’s stock worth $28,000 after acquiring an additional 292 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of Azenta by 44.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after acquiring an additional 385 shares in the last quarter. Rockefeller Capital Management L.P. grew its holdings in shares of Azenta by 98.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock valued at $46,000 after purchasing an additional 689 shares in the last quarter. Finally, Van ECK Associates Corp increased its position in Azenta by 141.2% in the fourth quarter. Van ECK Associates Corp now owns 1,585 shares of the company’s stock worth $53,000 after purchasing an additional 928 shares during the last quarter. Institutional investors own 99.08% of the company’s stock.

Azenta Stock Down 3.3%

Shares of AZTA opened at $27.37 on Friday. The business has a fifty day moving average of $23.69 and a 200 day moving average of $26.12. The company has a market cap of $1.26 billion, a PE ratio of -6.91 and a beta of 1.37. Azenta, Inc. has a 52-week low of $15.93 and a 52-week high of $41.73.

Azenta (NASDAQ:AZTA – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.16). The firm had revenue of $144.79 million for the quarter, compared to the consensus estimate of $148.47 million. Azenta had a negative net margin of 30.49% and a positive return on equity of 1.23%. The company’s revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.01 EPS.

Analyst Ratings Changes

A number of equities analysts have commented on AZTA shares. Needham & Company LLC dropped their price objective on shares of Azenta from $44.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Weiss Ratings raised shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $40.40.

Read Our Latest Stock Report on Azenta

About Azenta

(Free Report)

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.

Further Reading

Want to see what other hedge funds are holding AZTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Azenta, Inc. (NASDAQ:AZTA – Free Report).

Institutional Ownership by Quarter for Azenta (NASDAQ:AZTA)

Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.